Evidence map›Paper›PMID 42663690›Full record

ArticleNeurosurgical review2026

Endoscopic endonasal transcavernous surgery for knosp grade 3-4 growth hormone-secreting pituitary neuroendocrine tumors: surgical outcomes and predictors of biochemical remission.

Ling Tian, Min Liu, Mei Luo, Cheng Zhou, Jian Gu, Jiajun Zeng, Qin Shen, Zhongyi Tong, Yi Jiang, Bihua Luo and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ling TianDepartment of Neurosurgery, The Second Xiangya Hospital of Central South University, No. 139 Renmin Middle Road, Changsha, 410011, China.
Min LiuDepartment of Neurosurgery, The Second Xiangya Hospital of Central South University, No. 139 Renmin Middle Road, Changsha, 410011, China.
Mei LuoDepartment of Neurosurgery, The Second Xiangya Hospital of Central South University, No. 139 Renmin Middle Road, Changsha, 410011, China.
Cheng ZhouDepartment of Neurosurgery, The Second Xiangya Hospital of Central South University, No. 139 Renmin Middle Road, Changsha, 410011, China.
Jian GuDepartment of Neurosurgery, The Second Xiangya Hospital of Central South University, No. 139 Renmin Middle Road, Changsha, 410011, China.
Jiajun ZengDepartment of Neurosurgery, The Second Xiangya Hospital of Central South University, No. 139 Renmin Middle Road, Changsha, 410011, China.
Qin ShenDepartment of Radiology, The Second Xiangya Hospital of Central South University, Changsha, China.
Zhongyi TongDepartment of Pathology, The Second Xiangya Hospital of Central South University, Changsha, China.
Yi JiangDepartment of Pathology, The Second Xiangya Hospital of Central South University, Changsha, China.
Bihua LuoClinical Nursing Teaching and Research Section, The Second Xiangya Hospital of Central South University, Changsha, China.
Jian LinHealth Management Center, National Clinical Research Center for Metabolic Diseases, Hunan Provincial Clinical Medicine Research Center for Intelligent, Changsha, China.
Zhifeng ShengHealth Management Center, National Clinical Research Center for Metabolic Diseases, Hunan Provincial Clinical Medicine Research Center for Intelligent, Changsha, China.
Yong PengDepartment of Neurosurgery, The Second Xiangya Hospital of Central South University, No. 139 Renmin Middle Road, Changsha, 410011, China. foxpy195@csu.edu.cn.ORCID http://orcid.org/0000-0002-8778-0358

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Achieving biochemical remission in growth hormone-secreting pituitary neuroendocrine tumors (GH-PitNETs) with cavernous sinus invasion (Knosp grade 3-4) remains a significant surgical challenge. The objective was to evaluate the outcomes of the endoscopic endonasal transcavernous approach (transcavernous-EEA) and identify predictors of postoperative biochemical remission. This retrospective study included 50 patients with Knosp grade 3-4 GH-PitNETs. Patients were divided into two cohorts: Group 1 (prior to October 2020) received conventional EEA, while Group 2 (after October 2020) underwent transcavernous-EEA. The biochemical remission rate was significantly higher in Group 2 (64.7%) than in Group 1 (31.3%) (P = 0.027), with comparable surgery-related morbidity. In Group 2, preoperative IGF-1 (OR 0.984, 95% CI 0.969-0.999) and postoperative day 1 (POD1) GH levels (OR 0.241, 95% CI 0.076-0.760) were independently associated with biochemical remission in an exploratory multivariable analysis. Receiver operating characteristic curve analysis determined preliminary cutoff values of 587 ng/ml for preoperative IGF-1 (AUC 0.739, P = 0.007; Specificity 58.3%) and 2.185 ng/ml for POD1 GH (AUC 0.898, P < 0.001; Specificity 83.3%). Transcavernous-EEA was associated with higher biochemical remission during short-term follow-up in Knosp grade 3-4 GH-PitNETs without increasing surgical morbidity. Preoperative IGF-1 and POD1 GH levels may help stratify the likelihood of postoperative remission following this approach.

Indexed as

Cavernous SinusGrowth Hormone-Secreting Pituitary AdenomaNeuroendocrine TumorsNeuroendoscopyPituitary NeoplasmsAdultFemaleHuman Growth HormoneHumansInsulin-Like Growth Factor IMaleMiddle AgedRemission InductionRetrospective StudiesTreatment OutcomeHuman Growth HormoneInsulin-Like Growth Factor IBiochemical remissionEndoscopic endonasal approachGH-PitNETsKnosp gradeTranscavernous

Identifiers

PMID42663690

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.